9 October 2024 US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company.
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Beating many analysts’ expectations for the final quarter, Bristol Myers Squibb reported sales of $11.1 billion in its annual results statement, yielding full-year revenues of $42.5 billion. 4 February 2021
The China National Medical Products Administration (NMPA) has granted conditional approval to Xospata (gilteritinib) for the treatment of adult patients who have relapsed (disease that has returned) or refractory (resistant to treatment) acute myeloid leukemia (AML) with a FLT3 mutation (FLT3mut+) detected by a fully validated test. 4 February 2021
A scientific panel of the European Medicines Agency has kicked off a rolling review of NVX-CoV2373, a COVID‑19 vaccine being developed by US biotech Novavax. 4 February 2021
Swiss pharma giant Roche this morning announced 2020 financial results, showing that group sales increased 1% to 58.32 billion Swiss francs ($65.43 billion) at constant exchange rates (CER), but a 5% decline in Swiss francs, as a result of continued appreciation of the Swiss franc against most currencies, as well as biosimilars competition. 4 February 2021
The US Food and Drug Administration late yesterday granted accelerated approval to Tepmetko (tepotinib), from EMD Serono, the US healthcare business of Germany’s Merck KGaA for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. 4 February 2021
Setting the scene for an active M&A year for the biopharma sector, US biotech firm Jazz Pharmaceuticals today announced the biggest takeover deal so far this year. 3 February 2021
AbbVie, which has recently completed its $63 billion acquisition of Allergan, today announced financial results for the fourth quarter and full year ended December 31, 2020, that beat Wall Street forecasts, and pushing the firm’s shares 1.8% higher to $105.33 by mid-morning. 3 February 2021
For the fourth quarter of 2020, Biogen has reported revenues of $2.8 billion, hitting most analysts’ forecasts on the nose and bringing the total for the year to $13.4 billion. 3 February 2021
UK pharma major GlaxoSmithKline and German biotech firm CureVac today announced a new 150 million-euro ($180.5 million) collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. 3 February 2021
New York-based biopharma Immunovant lost 42% of its value in Tuesday’s trading after announcing a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401. 3 February 2021
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Beovu (brolucizumab) as an option in the National Health Service (NHS) for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults. 3 February 2021
A primary analysis of Phase III clinical trials indicates that COVID-19 Vaccine AstraZeneca - formerly known as AZD1222 - is safe and effective more than 22 days after the first dose. 3 February 2021
Feeling the effects of the coronavirus pandemic, Californian biotech Amgen reported mixed results for the final quarter of 2020, with rising revenues but declining profits. 3 February 2021
Life sciences investment group Abingworth has announced the final closing of its latest transatlantic venture fund, Abingworth Bioventures 8 (ABV 8) at $465 million. 3 February 2021
In a second research collaboration this year, privately-held US DNA-encoding specialist X-Chem has entered into a research collaboration and license agreement with Swiss pharma giant Roche’s subsidiary Genentech. 3 February 2021
French vaccines developer Valneva today reported that the UK government has exercised its option to order a further 40 million doses of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, for supply in 2022. 2 February 2021
Japan’s Ono Pharmaceutical has entered into a license agreement with US clinical-stage oncology company Ribon Therapeutics for RBN-2397, Ribon’s PARP7 (Poly ADP-ribose polymerase 7) inhibitor in Phase I clinical development for the treatment of cancer. 2 February 2021
China’s Clover Biopharmaceuticals is to begin a global Phase II/III trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum. 2 February 2021
Coherus BioSciences’ shares gained 12% yesterday, after it announced a collaboration with Shanghai Junshi Biosciences for the development and commercialization of toripalimab, the Chinese firm’s anti-PD-1 antibody, in the USA and Canada, which could be worth as much as $1.1billion to the latter. 2 February 2021